Your browser doesn't support javascript.
loading
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer.
Song, Honglin; Dicks, Ed M; Tyrer, Jonathan; Intermaggio, Maria; Chenevix-Trench, Georgia; Bowtell, David D; Traficante, Nadia; Group, Aocs; Brenton, James; Goranova, Teodora; Hosking, Karen; Piskorz, Anna; van Oudenhove, Elke; Doherty, Jen; Harris, Holly R; Rossing, Mary Anne; Duerst, Matthias; Dork, Thilo; Bogdanova, Natalia V; Modugno, Francesmary; Moysich, Kirsten; Odunsi, Kunle; Ness, Roberta; Karlan, Beth Y; Lester, Jenny; Jensen, Allan; Krüger Kjaer, Susanne; Høgdall, Estrid; Campbell, Ian G; Lázaro, Conxi; Pujara, Miguel Angel; Cunningham, Julie; Vierkant, Robert; Winham, Stacey J; Hildebrandt, Michelle; Huff, Chad; Li, Donghui; Wu, Xifeng; Yu, Yao; Permuth, Jennifer B; Levine, Douglas A; Schildkraut, Joellen M; Riggan, Marjorie J; Berchuck, Andrew; Webb, Penelope M; Group, Opal Study; Cybulski, Cezary; Gronwald, Jacek; Jakubowska, Anna; Lubinski, Jan.
Afiliação
  • Song H; Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • Dicks EM; Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • Tyrer J; Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • Intermaggio M; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
  • Chenevix-Trench G; Cancer Genetics, Queensland Institute of Medical Research-QIMR, Herston, Queensland, Australia.
  • Bowtell DD; Cancer Genomics and Genetics and Women's Cancer Programs, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Traficante N; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Group A; QIMR Berghofer Department of Genetics and Computational Biology, Herston, Queensland, Australia.
  • Brenton J; Department of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Goranova T; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • Hosking K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • Piskorz A; Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • van Oudenhove E; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, UK.
  • Doherty J; Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York, USA.
  • Harris HR; Huntsman Institute, University of Utah, Salt Lake City, Utah, USA.
  • Rossing MA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Duerst M; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Dork T; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Bogdanova NV; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Modugno F; Department of Gynaecology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Thüringen, Germany.
  • Moysich K; Gynaecology Research Unit, Hannover Medical School, Hannover, Niedersachsen, Germany.
  • Odunsi K; Department of Radiation Oncology, Hannover Medical School, Hannover, Niedersachsen, Germany.
  • Ness R; Department of Gynaecology, NN Alexandrov National Cancer Centre, Minsk, Minsk, Belarus.
  • Karlan BY; Womens Cancer Research Center, Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
  • Lester J; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Jensen A; Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Krüger Kjaer S; Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Høgdall E; School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Campbell IG; Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Lázaro C; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Pujara MA; Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Cunningham J; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Vierkant R; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Kobenhavn, Denmark.
  • Winham SJ; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark.
  • Hildebrandt M; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Kobenhavn, Denmark.
  • Huff C; Department of Pathology, Herlev Hospital, University of Copenhagen, Kobenhavn, Denmark.
  • Li D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Wu X; Department of Research, Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Yu Y; Hereditary Cancer Program, Catalan Institute of Oncology, Barcelona, Catalunya, Spain.
  • Permuth JB; Translational Research Laboratory, Catalan Institute of Oncology, Barcelona, Catalunya, Spain.
  • Levine DA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Schildkraut JM; Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Riggan MJ; Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Berchuck A; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Webb PM; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Group OS; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Cybulski C; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gronwald J; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jakubowska A; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Lubinski J; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Med Genet ; 58(5): 305-313, 2021 05.
Article em En | MEDLINE | ID: mdl-32546565
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Predisposição Genética para Doença / Proteína do Grupo de Complementação N da Anemia de Fanconi Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: J Med Genet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Predisposição Genética para Doença / Proteína do Grupo de Complementação N da Anemia de Fanconi Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: J Med Genet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido